| Document |
Document Title |
|
WO/2019/220293A1 |
Described herein is a perfluorinated aminoolefin compound of general formula (I): CFY=CXN(Rf)CF2Rf' where: (a) Rf and Rf' are (i) independently selected from a linear or branched perfluoroalkyl group having 1-8 carbon atoms, optionally c...
|
|
WO/2019/219016A1 |
Provided by the present invention are an acrylic compound and a preparation method therefor and a pharmaceutical composition and application thereof. In particular, the present invention provides a compound of formula I, wherein each gro...
|
|
WO/2019/217307A1 |
The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and me...
|
|
WO/2019/216810A1 |
Compounds of the formulae wherein the bond α is a single bond, a trans double bond (E), or a triple bond; X and Y are -CH2- or on of X and Y is O and the other is CH2; R1 is phenyl unsubstituted or substituted with one, two, or three su...
|
|
WO/2019/199621A1 |
The present invention is directed to bi-functional compounds which find use as pharmaceutical agents in the treatment of disease states and/or conditions which are through.macrophage migration inhibitory factor (MIF) or immunoglubin G (I...
|
|
WO/2019/199864A1 |
The present disclosure relates to tri-substituted aryl and heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for modulating autophagy or preventing, reversing, slowing or in...
|
|
WO/2019/193544A1 |
The present disclosure is related to the synthesis and applications of a benzo[a]phenoxazine. It displays good photophysical properties, such as high molar extinction coefficient, good fluorescence quantum yield and solubility in water. ...
|
|
WO/2019/193159A1 |
The present invention relates to bumetanide derivatives of formula (I) as well as pharmaceutical compositions comprising these compounds for use in the treatment or prevention of diseases/disorders involving Na+- K+- 2CI- - cotransporter...
|
|
WO/2019/190177A1 |
The present application relates to a novel pentadieonyl compound and a pharmaceutical composition comprising same. Functioning to restrain intracellular adipogenesis and fat accumulation within cells and to activate fat metabolism, the p...
|
|
WO/2019/175897A1 |
The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tau...
|
|
WO/2019/167080A1 |
The present invention disclosed herein is a bile acid sequestering composition comprising the resin chelate with improved affinity/binding activity towards bile acid(s) and to the process for preparation thereof.
|
|
WO/2019/161224A1 |
Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
|
|
WO/2019/138362A1 |
The field of this invention relates to a novel process, suitable for industrial scale manufacture, for the preparation of 4-(4-aminophenyl)morpholin-3-one of Formula (I), the key intermediate of rivaroxaban according to the scheme. In th...
|
|
WO/2019/129592A1 |
A method for preparing a fuel additive d is provided. The method comprises carrying out the following reaction: (l) The fuel additive d may be used as an octane-boosting additive in a fuel for a spark, ignition internal combustion engine.
|
|
WO/2019/129589A1 |
An optimised method for preparing a fuel additive f is provided. The method comprises carrying out the following reaction: (c, d, e) Starting material c may be prepared using an optimised method which comprises carrying out the following...
|
|
WO/2019/129594A1 |
A method for preparing a substituted fuel additive d is provided. The method comprises carrying out the following reaction: Each Y is independently selected from halides, and X is selected from -O- or -NR10-.
|
|
WO/2019/129588A1 |
Methods for preparing an octane-boosting fuel additive having the following formula: are provided. In a first aspect, the method may comprise carrying out the following reaction: (i), (ii) In a second aspect, the method may comprise: (1)...
|
|
WO/2019/129590A1 |
A method for preparing a substituted fuel additive d is provided. The method comprises carrying out the following reaction: (a) (b) (d), The fuel additive d may be used as an octane-boosting additive in a fuel for a spark- ignition inter...
|
|
WO/2019/129591A1 |
A method is provided for preparing a fuel additive having the formula: ( l ) The method comprises carrying out the following reactions: (i) addition of an alkylating agent b to starting material a: (a) to form an intermediate c; and (ii)...
|
|
WO/2019/133901A1 |
The present invention provides a method of using arylpiperazine derivatives for treating pulmonary fibrosis. The method comprises a step of administering to a pulmonary fibrosis patient in need thereof an effective amount of a compound o...
|
|
WO/2019/116262A1 |
A hydrofluoroolefin ether represented by the general Formula (I), compositions that include such compounds, and apparatuses and methods for use that include such compositions and compounds, wherein Formula (I) is represented by: Rf-O-CH2...
|
|
WO/2019/114811A1 |
The present application provides a method for synthesis of Roxadustat. A compound as represented by formula (VIII) is used as a raw material, and is reacted with phenol, a vinyl-containing ether, an acid, hydroxylamine, and then the prod...
|
|
WO/2019/118785A2 |
The present disclosure relates generally to therapeutic agents that may be useful inhibitors of Integrated Stress Response (ISR) pathway.
|
|
WO/2019/105915A1 |
The invention provides new heterocyclic compounds having the general formula (IA) wherein A, L, X, Y, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of ...
|
|
WO/2019/102186A1 |
There is provided compounds of formula (I) or pharmaceutically-acceptable salts thereof, wherein: L, X, R1, R2 and n have meanings provided in the description, which compounds are useful in the treatment of neurodegenerative and neuroinf...
|
|
WO/2019/094732A1 |
The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating diseases associated with the binding of CREB to CREB-binding protein (CBP) and...
|
|
WO/2019/085684A1 |
Disclosed in the present invention are a cyanobenzene-containing or thiocyanobenzene-containing compound and applications thereof in organic electroluminescent devices. The compound is formed by cyanobenzene or thiocyanobenzene groups, h...
|
|
WO/2019/090081A1 |
Provided herein are compounds of Formula (I) or Formula (II), compositions, and methods there of useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
|
|
WO/2019/090085A1 |
Provided herein are compounds of formula (I), compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions. (Formula I).
|
|
WO/2019/067389A1 |
Methods of treating developmental disorders and/or seizure disorders with etifoxine, a deuterated analog of etifoxine, or a pharmaceutically acceptable salt, solvate, or prodrug thereof are provided. The methods provide therapeutic compo...
|
|
WO/2019/067113A1 |
Described herein is an hydrofluorocarboximidate of formula (I) where: RH is a linear or branched alkyl group comprising 1 or 2 carbon atoms and (a) Rf1 and Rf2 are independently selected from a linear or branched perfluorinated alkyl gro...
|
|
WO/2019/044736A1 |
The present invention provides a detection method and detection probe for colibactin and colibactin-producing bacteria. The present invention provides, for example, the detection of myristoyl-asparagine using a tissue sample or stool sam...
|
|
WO/2019/039290A1 |
Provided are: an actinic ray-sensitive or radiation-sensitive resin composition that has excellent resolution, exposure latitude, and pattern shape properties; and a resist film, a pattern-forming method, a method for producing an electr...
|
|
WO/2019/038379A1 |
The present invention relates to a non-hygroscopic salt of the compound 2-(3-(4-propylheptyl)morpholino)ethan-1-ol having the INN name delmopinol. In particular, the invention relates to the citrate salt of delmopinol. The present invent...
|
|
WO/2019/040106A2 |
The present disclosure relates to compounds according to Formulae disclosed herein, useful for treating diseases.
|
|
WO/2019/029211A1 |
Disclosed by the present invention are an SIRT6 small-molecule allosteric activator and the application thereof, and provided is an SIRT6 small-molecule allosteric activator that contains a derivative as shown in formula (1) or a pharmac...
|
|
WO/2019/031470A1 |
[Problem] The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. [Solution] The invention provides: a compound represented by formula (I) o...
|
|
WO/2019/020654A1 |
The present application relates to a spirobifluorene derivative of a specific formula (I) which is suitable for use in electronic devices.
|
|
WO/2019/023147A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, c...
|
|
WO/2019/023145A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, ...
|
|
WO/2019/013244A1 |
Provided is a novel method for producing a (2S)-2-[(1H-pyrazol-1-yl)methyl]-1,3-oxazinane derivative. More specifically, a method for producing a (2S)-2-[(1H-pyrazol-1-yl)methyl]-1,3-oxazinane derivative represented by formula (1) is pro...
|
|
WO/2019/003820A1 |
Provided are: an active ester composition having high curability and exceptional properties such as dielectric properties and heat resistance in the cured product; a cured product of the composition; and a semiconductor sealing material ...
|
|
WO/2018/236913A1 |
Small molecule calpain modulator compositions and pharmaceutical compositions can be prepared and used as therapeutic agents. Exemplary compositions include non-macrocyclic a-keto amide derivatives. The therarapeutic agents can be used f...
|
|
WO/2018/234805A1 |
The present invention relates to compounds of formula (I). The compounds may be used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.
|
|
WO/2018/232675A1 |
Methylene blue (MB) derivatives selectively detect F-by desilylation reaction to act as a fluorescent probe.
|
|
WO/2018/229415A1 |
Sulphurised benzoxazine compound for use in the synthesis of a polybenzoxazine, corresponding to the formula (A), (formula I): wherein: each benzene ring of the two oxazine rings bears at least one radical denoted "G"; the two oxazine ri...
|
|
WO/2018/219882A1 |
The invention relates to a borated benzoxazine compound, particularly for use as a monomer for the synthesis of polybenzoxazine, said borated benzoxazine compound being of formula (A), in which: Z is an at least divalent, aliphatic, cycl...
|
|
WO/2018/215701A1 |
The invention relates to a halogenated benzoxazine compound, for use particularly as a monomer for the synthesis of polybenzoxazine, said halogenated benzoxazine compound being of formula (A) in which: each benzene ring of the two oxazin...
|
|
WO/2018/215700A1 |
The invention relates to a halogenated benzoxazine compound, for use in particular as a monomer for the synthesis of polybenzoxazine, said halogenated benzoxazine compound being of formula (A) (the symbol Hal representing at least one ha...
|
|
WO/2018/209445A1 |
There is described compounds, compositions, methods, and uses, of treating a subject having, suspected or having, or at risk of having, a prion disease, comprising: administering a cholesterol 24-hydroxylase (CH24OH)-activating compound.
|
